Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | NPY4R | P50391 | 14/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 9/20 | 0.40 |
| ▸ | NPY1R | P25929 | 9/20 | 0.40 |
| ▸ | NPY2R | P49146 | 6/20 | 0.40 |
| ▸ | CTSL | P07711 | 3/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.36 |
| ▸ | CTSK | P43235 | 3/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30264590 | 0.94 | APLNR (0.47) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30182954 | 0.94 | NPY4R (0.42) | SLC15A2APLNRNPY4RNPY5RNPY1R | |
| SCHEMBL29900214 | 0.94 | SLC15A2 (0.48) | SLC15A2APLNRNPY4RNPY5RNPY1R | |
| SCHEMBL30818464 | 0.91 | SLC15A2 (0.54) | SLC15A2APLNRNPY4RNPY5RNPY1R | |
| SCHEMBL31064774 | 0.91 | SLC15A2 (0.54) | SLC15A2APLNRNPY4RNPY5RNPY1R | |
| SCHEMBL30390767 | 0.90 | NPY4R (0.46) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL29484316 | 0.90 | NPY4R (0.42) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31412180 | 0.89 | QRFPR (0.45) | SLC15A2APLNRNPY4RNPY5RNPY1R | |
| SCHEMBL30391081 | 0.88 | NPY4R (0.43) | APLNRNPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL30390440 | 0.88 | NPY4R (0.43) | APLNRNPY4RNPY5RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129496-A9 | RNAS FOR COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4346844-A1 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | Apellis Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4308591-A1 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AFFILOGIC (FR) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022251484-A9 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023278698-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-4103716-A1 | RNAS FOR COMPLEMENT INHIBITION | Apellis Pharmaceuticals, Inc. (US) | 2022-12-21 | — | — | EP | disclosed |
| WO-2022251484-A1 | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | APELLIS PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022198108-A1 | POLYPEPTIDES FOR COMPLEMENT INHIBITION | AFFILOGIC (FR) | 2022-09-22 | — | — | WO | disclosed |
| EP-3996744-A1 | VIRAL VECTOR THERAPY | Apellis Pharmaceuticals, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |